Geoff von Maltzahn, Tessera Therapeutics CEO

Flag­ship-found­ed Tessera fu­els up with $300M 'to go on a re­al­ly big ad­ven­ture' in gene edit­ing

A few years ago, the gene edit­ing ap­proach at Tessera was just a “twin­kle in our eye,” CEO and co-founder Ge­off von Maltzahn said.

Nu­cle­as­es — the cru­cial ma­chin­ery un­der­ly­ing the gene edit­ing field — do a pret­ty good job of cut­ting DNA, al­low­ing sci­en­tists to switch off a spe­cif­ic gene. But von Maltzahn and Ja­cob Rubens, Tessera’s co-founder and chief in­no­va­tion of­fi­cer, saw the op­por­tu­ni­ty in be­ing able to do more.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA